Administration of desmopressin in brain-dead donors and renal function in kidney recipients

What Was Tested

Researchers studied Vasopressin and Desmopressin in this randomized controlled trial publication.

In 175 kidney recipients (controls n=89, desmopressin group n=86) the researchers measured serum concentrations of creatinine and haemodialysis requirements to assess early renal function in the first 15 days after transplantation.

Why It Was Studied

The use of desmopressin to limit the consequences of diabetes insipidus is controversial.

The researchers assessed the effects of desmopressin administered to brain-dead donors on early and long-term graft function in kidney recipients.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The researchers assessed long-term results of transplantation (median time 45 months) for a homogeneous subgroup of 95 recipients (48 in the desmopressin group).

What Was Measured

The researchers assessed the effects of desmopressin administered to brain-dead donors on early and long-term graft function in kidney recipients.

PubMed files the paper under topics including Brain Death, Creatinine, Deamino Arginine Vasopressin, Diabetes Insipidus, Graft Survival, Kidney Transplantation and Renal Agents.

What This Means in Plain Language

The paper is a randomized study of Vasopressin and Desmopressin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1998 (Lancet (London, England)), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.